Fig. 6: Prophylactic and therapeutic efficacy of B026 and A138 in a high-dose VACV-challenge mouse model.
A Schematic diagram of the prophylactic and therapeutic models. C57BL/6 mice were randomly divided into 4 groups (n = 6 per group). For the prophylactic model, mice were injected intraperitoneally (i.p.) with PBS, individual antibodies (A138 or B026) or antibody cocktail (A138 and B026) at 24 hrs before challenged with a high-dose (109 PFU) of VACV. For the therapeutic model, mice were injected i.p. 24 hrs after challenge with 109 PFU VACV. Body weight (B, D) and survival curves (C, E) were recorded. B, C show data for prophylactic model while (D) and (E) for the therapeutic model. F, G Viral titers in the lungs and spleen of mice in the prophylactic (F) and therapeutic groups (G). The data represent means ± SEM, indicated by error bars. The significance of differences between groups was assessed using one-way ANOVAs followed by Dunnett’s multiple comparisons test for multiple comparisons. Source data are provided as a Source Data file.
